Study of a new drug with topotecan for relapsed small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether adding a new investigational drug (IBB0979) to the standard chemotherapy topotecan helps people with small cell lung cancer whose cancer has come back after earlier treatment. The goal is to see if the combination is more effective than topotecan alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have small cell lung cancer that has returned or worsened after first or second-line treatment.
- You have at least one tumor that can be measured on scans.
- You are able to take care of yourself (ECOG score 0 or 1).
- Your doctor expects you to live at least 3 more months.
- Your organs (like liver, kidneys, blood) are working well enough to receive the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HS-20093 against a standard drug (topotecan) for people with small cell lung cancer that has returned after initial treatment. The goal is to see which drug works better.
This trial is testing a new treatment (JK-1201I) against a standard chemotherapy (topotecan) for people with extensive-stage small cell lung cancer that has come back after first-line treatment. The goal is to see if the new treatment works better at controlling the cancer.
This trial tests a new drug called IBI3009 for people with advanced small cell lung cancer that cannot be removed by surgery. It aims to see how safe the drug is and how well it works against the cancer.
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
This trial tests a new drug called ABBV-706 against standard treatments (topotecan, lurbinectedin, or amrubicin) for people with small cell lung cancer that has come back or stopped responding to previous therapies. The goal is to see if ABBV-706 works better at controlling the cancer.
This trial tests a new drug, NMS-03305293, in adults with small cell lung cancer that has come back after earlier treatments. The goal is to see if it can help shrink or slow the cancer.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.